Axis 1

Oncogenic pathways in cancer: From modelization towards targeted therapy

Research works

The establishment of an oncogenic state is a complex process characterized by the accumulation of genetic and epigenetic events that eventually lead to malignant cancer. The development of engineered organisms in which are activated particular oncogenic pathways in specific tissues opens new challenges and have several perspectives: it allows to decipher biological mechanisms by which oncogenic pathways perturb normal tissue development. It helps to understand the multi-step process of the disease from the initiation to malignant transformation. It allows to explore at the molecular and functional levels the cross-talk between cancer cells and their microenvironment. Finally, it aims to develop therapies that specifically target markers and/or biological mechanisms involved in cancer development and resistance.

The goal of the Axis 1 is to federate researchers, staff members and students from the CRCT on a thematic entitled “Oncogenic pathways in cancer: From modelization towards targeted therapy”, in order to share multi-disciplinary expertise including the use of transgenic mice or patient-derived xenograft models, of functional in vitro and in vivo experiments with primary cells, of next generation sequencing associated with computational analysis, of chemical and molecular screening approaches, with the common prospect to understand and target cell-autonomous and non-cell autonomous oncogenic pathways in cancer.

Coordination Julie Guillermet and Bastien Gerby

research teams
involved in this axix

Team

Gilles Favre, Olivier Sordet + 29 collaborators

SIGNATHER : Signalisation cellulaire, oncogenèse et thérapeutiques

+
team

Corinne Bousquet + 18 collaborators

MICROPANC : Microenvironnement & Résistante Thérapeutique dans les Néoplasies Pancréatiques

 
 
+
team

Camille Laurent + 21 collaborators

NoLymIT : Nouvelles immunothérapies contre les lymphomes

+
team

Pierre Cordelier + 21 collaborators

ImPact : Innovation thérapeutique dans le cancer du pancréas

+
team

Elizabeth Cohen-Jonathan Moyal +22 collaborators

RADOPT : Optimisation de la radiothérapie: des voies de signalisation moléculaires aux essais cliniques

+
team

Marc Poirot, Sandrine Silvente-Poirot + 15 collaborators

Métabolisme du cholestérol et innovations thérapeutiques

+
team

Eric Delabesse + 18 collaborators

ALTFAL : Altération des facteurs de transcription dans les leucémies aigües

+
team

Julie Guillermet-Guibert + 11 collaborators

SigDYN : Intégration des signaux cellulaires & PI3K de classe I, II, III.

+
team

Jean-Emmanuel Sarry + 31 collaborators

METAMAL : Métabolisme et résistance thérapeutique dans les leucémies aiguës myéloïdes

+
team

Frédéric Chibon + 10 collaborators

ONCOSARC – Oncogenèse des sarcomes

+
team

Véra Pancaldi+ 10 collaborators

NetB(IO)² : Network Biology for Immuno-oncology

+
Centre de Recherches en Cancérologie de Toulouse

Centre de Recherches contre le Cancer de Toulouse (Oncopole)

Toulouse - FR

Nous contacter

+33 5 82 74 15 75

Nous rejoindre ?

Pin It on Pinterest